AIT Therapeutics (OTCMKTS:AITB) Stock Price Up 0.2%

AIT Therapeutics Inc (OTCMKTS:AITB)’s stock price rose 0.2% during mid-day trading on Friday . The stock traded as high as $5.66 and last traded at $5.40, approximately 4,421 shares traded hands during mid-day trading. A decline of 77% from the average daily volume of 19,539 shares. The stock had previously closed at $5.39.

Separately, Zacks Investment Research raised Booz Allen Hamilton from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a report on Friday, June 28th.

The firm has a fifty day moving average price of $5.33. The stock has a market cap of $57.14 million, a P/E ratio of -1.78 and a beta of -0.31.

AIT Therapeutics (OTCMKTS:AITB) last issued its quarterly earnings data on Tuesday, June 25th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.13). The business had revenue of $7.70 million during the quarter, compared to analysts’ expectations of $2.75 million. Sell-side analysts expect that AIT Therapeutics Inc will post -0.78 EPS for the current year.

AIT Therapeutics Company Profile (OTCMKTS:AITB)

AIT Therapeutics, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Further Reading: Asset Allocation and Your Retirement

Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with's FREE daily email newsletter.